Madeleine Tavcar

About Madeleine Tavcar

Madeleine is an associate in the Life Sciences Transactions team in our New York office.  Prior to joining Freshfields, Madeleine worked at a full-service law firm where she focused on representing life sciences clients in connection with licensing arrangements, research and development collaborations, intellectual property transfers and patent prosecution. Prior to that, she worked as a Patent Prosecution Consultant with BioPharmX where she prepared and prosecuted patent applications in the pharmaceutical space, both domestically and internationally, and as an Associate Scientist at a multinational pharmaceutical company where she designed and conducted validation and verification studies to evaluate performance characteristics of hematology products.

Madeleine earned her J.D. from Santa Clara University Law School and her Bachelor of Science degree in Biochemistry with a minor in Biotechnology from Santa Clara University in Santa Clara, California.

Recent work

• AstraZeneca on its pending acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.
• AstraZeneca on its acquisition of Gracell Biotechnologies.
• AstraZeneca on its $1.1bn acquisition of Icosavax.
• BioCryst in its license agreement with Clearside Biomedical, Inc. to develop and commercialize BioCryst’s proprietary compound avoralstat in combination with Clearside’s proprietary drug delivery device.